Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: The GUSTO-I experience

Journal of the American College of Cardiology

Volumn 32, Issue 3, 1998, Pages 634-640

  Pfisterer, Matthias ^a   Cox, Jafna L ^b   Granger, Christopher B ^c   Brener, Sorin J ^d   Naylor, C David ^b   Califf, Robert M ^c   Van De Werf, Frans ^e   Stebbins, Amanda L ^c   Lee, Kerry L ^c   Topol, Eric J ^d   Armstrong, Paul W ^f  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ATENOLOL; HEPARIN; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD CLOT LYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; FEMALE; HEART TAMPONADE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; AGED; ATENOLOL; CAUSE OF DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK; STREPTOKINASE; SURVIVAL RATE; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 0031667044     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00279-4     Document Type: Article

References (16)

1. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarctions ISIS-2 . Lancet. 2:1988;349-360.
2. Indications for fibrinolytic therapy in suspected acute myocardial infarction collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients . Lancet. 343:1994;311-322.
3. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction results of the Survival and Ventricular Enlargement Trial . N Engl J Med. 327:1992;669-677.
4. Yusuf S., Peto R., Lewis J., Collins R., Sleight P. Beta blockade during and after myocardial infarction. Prog Cardiovasc Dis. 27:1985;335-371.
5. Yusuf S., Wittes J., Friedman L. Overview of results of randomized clinical trials in heart disease. JAMA. 260:1988;2088-2093.
6. A randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction. Lancet. 2:1986;57-66.
7. Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction ISIS-1 . Lancet. 1:1988;921-923. Erratum published Lancet 1988;2:292.
8. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial . N Engl J Med. 320:1989;618-627.
9. Gore J.M., Sloan M., Price T.R., et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Circulation. 83:1991;448-459.
10. Van de Werf F., Janssens L., Brzostek T., et al. Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardic agent in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol. 22:1993;407-416.
11. Guidelines for the early management of patients with acute myocardial infarction A report of the American College of Cardiology/American Heart Association task force on assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee to develop guidelines for the early management of patients with acute myocardial infarction) . J Am Coll Cardiol. 16:1990;249-292.
12. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682.
13. Lee K.L., Woodlief L.H., Topol E.J., et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction results from an international trial of 41,021 patients . Circulation. 91:1995;1659-1668.
14. Gore J.M., Granger C.B., Simoons M.L., et al. Stroke after thrombolysis mortality and functional outcomes in the GUSTO-I trial . Circulation. 92:1995;2811-2818.
15. Rogers W.J., Bowlby L.J., Chandra N.C., et al. Treatment of myocardial infarction in the United States (1990 to 1993) Observations from the National Registry of Myocardial Infarction . Circulation. 90:1994;2103-2114.
16. Kleiman N.S., White H.D., Ohman E.M., et al. Mortality within 24 hours of thrombolysis for myocardial infarction the importance of early reperfusion . Circulation. 90:1994;2658-2665.